logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

mBCa: 5-year data back paclitaxel with trastuzumab-pertuzumab

Median PFS was 24.2 months and OS not reached in the phase 2 study.